Gliclazide Use in End-Stage Renal Failure

Introduction to Gliclazide

Gliclazide is one of the preferred sulfonylureas that can be safely used in patients with end-stage renal failure (ESRF), with appropriate dose adjustment and careful monitoring for hypoglycemia, as recommended by the American Journal of Kidney Diseases 1

Among second-generation sulfonylureas, gliclazide is preferred in advanced kidney disease because it does not have active metabolites and does not significantly increase the risk of hypoglycemia in patients with chronic kidney disease (CKD), according to the American Journal of Kidney Diseases 1
Unlike first-generation sulfonylureas, which should be completely avoided in CKD, gliclazide can be used with appropriate dose adjustments, as stated by the American Journal of Kidney Diseases 3

The American College of Cardiology is not mentioned, however, the dosing is as follows: Start with a lower initial dose (e.g., 30mg daily) in ESRF patients and titrate cautiously based on blood glucose response, as recommended by Praxis Medical Insights 2
Consider less stringent glycemic targets (HbA1c ~7-8%) for ESRF patients on gliclazide to minimize hypoglycemia risk, according to Endocrine Reviews and the American Journal of Kidney Diseases 4, 5

Gliclazide's metabolism primarily occurs in the liver rather than the kidneys, making it safer in renal impairment compared to other sulfonylureas, as reported by the American Journal of Kidney Diseases 3

Patients with ESRF are at increased risk of hypoglycemia due to decreased renal gluconeogenesis, as stated by the American Journal of Kidney Diseases 1
Patients with ESRF are at increased risk of hypoglycemia due to impaired insulin clearance, as reported by Endocrine Reviews 4
Patients with ESRF are at increased risk of hypoglycemia due to defective insulin degradation due to uremia, according to Endocrine Reviews 6

If gliclazide is not tolerated or contraindicated, consider DPP-4 inhibitors, such as Linagliptin, which requires no dose adjustment in ESRF, as recommended by Endocrine Reviews and Praxis Medical Insights 2, 7
If gliclazide is not tolerated or contraindicated, consider Repaglinide, starting with 0.5mg with meals if eGFR <30 mL/min/1.73m², as stated by Endocrine Reviews and Praxis Medical Insights 2, 7
If gliclazide is not tolerated or contraindicated, consider Pioglitazone, with no dose adjustment required but use with caution due to fluid retention risk, according to Endocrine Reviews and Praxis Medical Insights 2, 7

Metformin is contraindicated due to risk of lactic acidosis, as reported by Endocrine Reviews and Praxis Medical Insights 2, 7
Glyburide is contraindicated in ESRF, according to Endocrine Reviews 8
Exenatide is contraindicated in ESRF, as stated by Endocrine Reviews 7
Alpha-glucosidase inhibitors (acarbose, miglitol) are contraindicated in ESRF, as reported by Endocrine Reviews 7, 8

More frequent blood glucose monitoring is essential in ESRF patients on any antidiabetic medication, as recommended by Praxis Medical Insights 2
HbA1c may be less reliable in ESRF due to reduced red blood cell lifespan, anemia, and other factors affecting hemoglobin, according to Endocrine Reviews 4, 6
An HbA1c range of 7% to 8% appears most favorable based on observational data for associations with mortality and risks of hypoglycemia with intensive glycemic control regimens in advanced CKD, as reported by Endocrine Reviews 4
Consider continuous glucose monitoring in ESRF patients for more precise monitoring and treatment adjustments, as recommended by Endocrine Reviews 4, 6